S&P 500   3,762.54 (-0.55%)
DOW   30,095.80 (-0.59%)
QQQ   280.60 (-0.49%)
AAPL   145.84 (-0.38%)
MSFT   248.20 (-0.40%)
META   139.36 (+0.27%)
GOOGL   101.87 (+0.43%)
AMZN   120.17 (-0.64%)
TSLA   237.21 (-1.49%)
NVDA   132.05 (-0.03%)
NIO   14.82 (-7.61%)
BABA   84.31 (-0.09%)
AMD   68.47 (+0.78%)
T   15.44 (-3.08%)
MU   54.18 (-1.00%)
CGC   2.93 (-4.56%)
F   12.38 (-1.04%)
GE   66.27 (-1.73%)
DIS   100.56 (-0.24%)
AMC   7.33 (+0.00%)
PYPL   94.62 (+0.84%)
PFE   43.36 (-1.72%)
NFLX   237.25 (+0.22%)
S&P 500   3,762.54 (-0.55%)
DOW   30,095.80 (-0.59%)
QQQ   280.60 (-0.49%)
AAPL   145.84 (-0.38%)
MSFT   248.20 (-0.40%)
META   139.36 (+0.27%)
GOOGL   101.87 (+0.43%)
AMZN   120.17 (-0.64%)
TSLA   237.21 (-1.49%)
NVDA   132.05 (-0.03%)
NIO   14.82 (-7.61%)
BABA   84.31 (-0.09%)
AMD   68.47 (+0.78%)
T   15.44 (-3.08%)
MU   54.18 (-1.00%)
CGC   2.93 (-4.56%)
F   12.38 (-1.04%)
GE   66.27 (-1.73%)
DIS   100.56 (-0.24%)
AMC   7.33 (+0.00%)
PYPL   94.62 (+0.84%)
PFE   43.36 (-1.72%)
NFLX   237.25 (+0.22%)
S&P 500   3,762.54 (-0.55%)
DOW   30,095.80 (-0.59%)
QQQ   280.60 (-0.49%)
AAPL   145.84 (-0.38%)
MSFT   248.20 (-0.40%)
META   139.36 (+0.27%)
GOOGL   101.87 (+0.43%)
AMZN   120.17 (-0.64%)
TSLA   237.21 (-1.49%)
NVDA   132.05 (-0.03%)
NIO   14.82 (-7.61%)
BABA   84.31 (-0.09%)
AMD   68.47 (+0.78%)
T   15.44 (-3.08%)
MU   54.18 (-1.00%)
CGC   2.93 (-4.56%)
F   12.38 (-1.04%)
GE   66.27 (-1.73%)
DIS   100.56 (-0.24%)
AMC   7.33 (+0.00%)
PYPL   94.62 (+0.84%)
PFE   43.36 (-1.72%)
NFLX   237.25 (+0.22%)
S&P 500   3,762.54 (-0.55%)
DOW   30,095.80 (-0.59%)
QQQ   280.60 (-0.49%)
AAPL   145.84 (-0.38%)
MSFT   248.20 (-0.40%)
META   139.36 (+0.27%)
GOOGL   101.87 (+0.43%)
AMZN   120.17 (-0.64%)
TSLA   237.21 (-1.49%)
NVDA   132.05 (-0.03%)
NIO   14.82 (-7.61%)
BABA   84.31 (-0.09%)
AMD   68.47 (+0.78%)
T   15.44 (-3.08%)
MU   54.18 (-1.00%)
CGC   2.93 (-4.56%)
F   12.38 (-1.04%)
GE   66.27 (-1.73%)
DIS   100.56 (-0.24%)
AMC   7.33 (+0.00%)
PYPL   94.62 (+0.84%)
PFE   43.36 (-1.72%)
NFLX   237.25 (+0.22%)
NASDAQ:TRIL

Trillium Therapeutics - TRIL Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$18.44
$18.44
50-Day Range
$17.50
$18.44
52-Week Range
$5.80
$20.96
Volume
8 shs
Average Volume
1.87 million shs
Market Capitalization
$1.94 billion
P/E Ratio
29.74
Dividend Yield
N/A
Price Target
N/A
TRIL stock logo

About Trillium Therapeutics (NASDAQ:TRIL) Stock

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRIL Stock News Headlines

10 Psychedelics CEOs To Pay Attention To In 2022
Is Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?
Why Investors Should Love Pfizer's Acquisition of Trillium
See More Headlines

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRIL Company Calendar

Last Earnings
11/18/2021
Today
10/06/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRIL
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Net Income
$-59,350,000.00
Pretax Margin
-113,720.92%

Debt

Sales & Book Value

Annual Sales
$150,000.00
Price / Sales
12,907.39
Book Value
$2.56 per share

Miscellaneous

Free Float
95,440,000
Market Cap
$1.94 billion
Optionable
Optionable
Beta
2.08

Key Executives

  • Jan Skvarka
    President, Chief Executive Officer & Director
  • James T. Parsons
    Chief Financial Officer
  • Robert A. UgerRobert A. Uger
    Chief Scientific Officer
  • Kathleen Large
    Senior Vice President-Clinical Operations
  • Ingmar Bruns
    Chief Medical Officer













TRIL Stock - Frequently Asked Questions

Should I buy or sell Trillium Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TRIL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRIL, but not buy additional shares or sell existing shares.
View TRIL analyst ratings
or view top-rated stocks.

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) announced its earnings results on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately $18.44.

How much money does Trillium Therapeutics make?

Trillium Therapeutics (NASDAQ:TRIL) has a market capitalization of $1.94 billion and generates $150,000.00 in revenue each year. The biotechnology company earns $-59,350,000.00 in net income (profit) each year or $0.62 on an earnings per share basis.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The official website for the company is www.trilliumtherapeutics.com. The biotechnology company can be reached via phone at (416) 595-0627 or via email at james@trilliumtherapeutics.com.

This page (NASDAQ:TRIL) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.